including semaglutide branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use
Whether someone is just starting GLP-1s or has been on them for a while, this guide explains what they might experience and how to help manage those symptoms
Initiation of GLP-1 receptor agonists in post-bariatric patients follows similar protocols to other populations, with gradual dose escalation to minimise gastrointestinal side effects
GLP-1 has a direct effect on adipose tissue
Rare but serious risks include pancreatitis (requiring immediate medical attention if severe abdominal pain occurs), gallbladder disease, and potential thyroid C-cell tumors (based on rodent studies)
The pharmacy is not located within the U.S